Synonym
Kwd 2131; Kwd2131; Kwd-2131
IUPAC/Chemical Name
1-(3,5-Dihydroxyphenyl)-2-((1,1-dimethyl-2-hydroxyethyl)amino)ethanol sulfate
InChi Key
VCVQRMXBPWNUSW-UHFFFAOYSA-N
InChi Code
InChI=1S/C12H19NO4.H2O4S/c1-12(2,7-14)13-6-11(17)8-3-9(15)5-10(16)4-8;1-5(2,3)4/h3-5,11,13-17H,6-7H2,1-2H3;(H2,1,2,3,4)
SMILES Code
OCC(NCC(O)C1=CC(O)=CC(O)=C1)(C)C.O=S(O)(O)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
339.36
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Hegardt B, Arner B. Evaluation of the inhibition of allergen-induced intracutaneous reactions by a new beta-agonist, KWD 2131, and by terbutaline. Eur J Respir Dis. 1981 Oct;62(5):352-9. PMID: 6124440.
2: Hegardt B, Löwhagen O, Svedmyr N. New beta-agonist, KWD 2131, compared with terbutaline in asthmatics. A cumulative dose-response study. Allergy. 1980 Mar;35(2):105-12. doi: 10.1111/j.1398-9995.1980.tb01724.x. PMID: 6104451.
3: Hegardt B, Pauwels R, Van Der Straeten M. Inhibitory effect of KWD 2131, terbutaline, and DSCG on the immediate and late allergen-induced bronchoconstriction. Allergy. 1981 Feb;36(2):115-22. doi: 10.1111/j.1398-9995.1981.tb04105.x. PMID: 6112931.
4: Hegardt B, Löwhagen O, Svedmyr N. Histamine-induced bronchospasm. Its reproducibility and usage in clinical evaluation of the sub-threshold bronchodilating dose of a new beta-agonist, KWD 2131. Allergy. 1980 Mar;35(2):113-21. doi: 10.1111/j.1398-9995.1980.tb01725.x. PMID: 6104452.
5: Hegardt B, Löwhagen O, Svedmyr N, Granerus G. The protective property of equipotent bronchodilating doses of inhaled KWD 2131 and terbutaline against allergen-induced bronchospasm. Allergy. 1982 Aug;37(6):407-16. doi: 10.1111/j.1398-9995.1982.tb02319.x. PMID: 7137535.
6: Strandberg K, Pegelow KO, Persson CG, Sörenby L. Anti-anaphylactic and bronchodilating action of a beta-adrenoceptor stimulator, KWD 2131, in human lung tissue. Allergy. 1979 Aug;34(4):221-4. doi: 10.1111/j.1398-9995.1979.tb01702.x. PMID: 92896.
7: Pegelow KO, Strandberg K. Evaluation of the bronchodilating and antiallergic properties of a beta-adrenoceptor stimulant, KWD 2131, in asthmatic patients. Allergy. 1980 Sep;35(6):509-19. doi: 10.1111/j.1398-9995.1980.tb01798.x. PMID: 6110383.
8: Svensson G, Hegardt B, Löfkvist T. Effects of topical use of beta- adrenoceptor stimulants of nasal mucosa. Rhinomanometric evaluations in experiments with terbutaline and KWD 2131. Acta Otolaryngol. 1980 Sep- Oct;90(3-4):297-303. doi: 10.3109/00016488009131729. PMID: 6110308.
9: Svensson G, Hegardt B, Löfkvist T. Influence of a beta-adrenoceptor stimulant, KWD 2131, in nasal histamine provocation tests. Rhinomanometric evaluations in normal persons and patients with hay fever. Acta Otolaryngol. 1981 Nov-Dec;92(5-6):535-41. doi: 10.3109/00016488109133293. PMID: 6171989.
10: Hegardt B, Löwhagen O, Svedmyr N. Evaluation of the protective effect of a new beta-agonist, KWD 2131, on allergen-induced bronchospasm. Allergy. 1980 Jul;35(5):413-9. doi: 10.1111/j.1398-9995.1980.tb01787.x. PMID: 6108726.
